WO2000035436A3 - Traitement de l'arthrite a l'aide d'inhibiteurs de la mek - Google Patents

Traitement de l'arthrite a l'aide d'inhibiteurs de la mek Download PDF

Info

Publication number
WO2000035436A3
WO2000035436A3 PCT/US1999/029783 US9929783W WO0035436A3 WO 2000035436 A3 WO2000035436 A3 WO 2000035436A3 US 9929783 W US9929783 W US 9929783W WO 0035436 A3 WO0035436 A3 WO 0035436A3
Authority
WO
WIPO (PCT)
Prior art keywords
arthritis
treatment
mek inhibitors
formula
suspected
Prior art date
Application number
PCT/US1999/029783
Other languages
English (en)
Other versions
WO2000035436A2 (fr
Inventor
David Thomas Dudley
Craig Mason Flory
Alan Robert Saltiel
Original Assignee
Warner Lambert Co
David Thomas Dudley
Craig Mason Flory
Alan Robert Saltiel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, David Thomas Dudley, Craig Mason Flory, Alan Robert Saltiel filed Critical Warner Lambert Co
Priority to EP99966278A priority Critical patent/EP1143957A3/fr
Priority to AU21858/00A priority patent/AU776788C/en
Priority to HU0104693A priority patent/HUP0104693A3/hu
Priority to JP2000587757A priority patent/JP2002532415A/ja
Priority to IL14323699A priority patent/IL143236A0/xx
Priority to CA002346448A priority patent/CA2346448A1/fr
Publication of WO2000035436A2 publication Critical patent/WO2000035436A2/fr
Publication of WO2000035436A3 publication Critical patent/WO2000035436A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention se rapporte à un procédé de prévention et de traitement de l'arthrite chez un mammifère souffrant d'arthrite et nécessitant un traitement, ou supposé enclin à souffrir d'arthrite. Ledit procédé consiste à administrer une quantité anti-arthritique efficace d'un inhibiteur de la kinase MEK, et notamment un composé représenté par la formule (I) et la formule (II).
PCT/US1999/029783 1998-12-16 1999-12-15 Traitement de l'arthrite a l'aide d'inhibiteurs de la mek WO2000035436A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP99966278A EP1143957A3 (fr) 1998-12-16 1999-12-15 Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
AU21858/00A AU776788C (en) 1998-12-16 1999-12-15 Treatment of arthritis with MEK inhibitors
HU0104693A HUP0104693A3 (en) 1998-12-16 1999-12-15 Treatment of arthritis with mek inhibitors
JP2000587757A JP2002532415A (ja) 1998-12-16 1999-12-15 Ｍｅｋ阻害剤による関節炎の治療
IL14323699A IL143236A0 (en) 1998-12-16 1999-12-15 Treatment of arthritis with mek inhibitors
CA002346448A CA2346448A1 (fr) 1998-12-16 1999-12-15 Traitement de l'arthrite a l'aide d'inhibiteurs de la mek

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11254498P 1998-12-16 1998-12-16
US60/112,544 1998-12-16
US16465199P 1999-11-10 1999-11-10
US60/164,651 1999-11-10

Publications (2)

Publication Number Publication Date
WO2000035436A2 WO2000035436A2 (fr) 2000-06-22
WO2000035436A3 true WO2000035436A3 (fr) 2001-10-18

Family

ID=26810075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029783 WO2000035436A2 (fr) 1998-12-16 1999-12-15 Traitement de l'arthrite a l'aide d'inhibiteurs de la mek

Country Status (8)

Country Link
EP (1) EP1143957A3 (fr)
JP (1) JP2002532415A (fr)
KR (1) KR100609800B1 (fr)
AU (1) AU776788C (fr)
CA (1) CA2346448A1 (fr)
HU (1) HUP0104693A3 (fr)
IL (1) IL143236A0 (fr)
WO (1) WO2000035436A2 (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515567A (en) * 1999-07-16 2004-03-26 Warner Lambert Co Method for treating chronic pain using MEK inhibitors
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
HUP0202381A3 (en) * 1999-07-16 2004-12-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
KR20020096368A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 연골세포의 분화촉진, 연골세포의 탈분화 억제 또는탈분화된 연골세포의 재분화 촉진제, 그것의 스크리닝방법 및 그것을 이용한 연골세포의 제조방법
KR20020096367A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 관절염 예방 또는 치료제 및 그것의 스크리닝 방법
CA2532067C (fr) 2003-07-24 2010-12-21 Stephen Douglas Barrett Benzimidazoles n-methyle-substitues
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
ME01480B (fr) 2004-06-11 2014-04-20 Japan Tobacco Inc Dérivés de 5-amino-2,4,7-trioxo-3,4,7,8-tétrahydro-2h-pyrido'2,3-d! pyrimidine et composés apparentés pour le traitement du cancer
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7999006B2 (en) 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
CA2709257C (fr) 2007-12-19 2016-12-13 Cancer Research Technology Limited Composes pyrido[2,3-b]pyrazine substitues en position 8 et leur utilisation
JP5746630B2 (ja) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換スルホンアミドフェノキシベンズアミド
EP3998479A1 (fr) * 2008-12-19 2022-05-18 Medirista Biotechnologies AB Cardiolopide oxydée en tant que nouveau facteur pro-inflammatoire
EP2491014A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Dérivés d'halogénophénoxybenzamide substitués
WO2011047795A1 (fr) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Benzosulfonamides substitués
CA2777304A1 (fr) 2009-10-21 2011-04-28 Marion Hitchcock Benzosulfonamides substitues
BR112012018415A2 (pt) 2010-02-01 2020-08-04 Cancer Research Technology Limited composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto.
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
EP3812387A1 (fr) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de protéine kinase hétérocycliques
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
EP2909181B1 (fr) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Modulateurs de pkm2 et procédés pour les utiliser
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970205B1 (fr) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
CN105007950B (zh) 2013-03-15 2019-01-15 诺华股份有限公司 抗体药物缀合物
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
WO2016024195A1 (fr) 2014-08-12 2016-02-18 Novartis Ag Conjugués médicament-anticorps anti-cdh6
CA2960824A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Therapies combinees d'inhibiteurs d'alk
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
CN108064244B (zh) 2014-11-14 2021-09-17 诺华股份有限公司 抗体药物缀合物
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
HUE043060T2 (hu) 2014-12-23 2019-07-29 Novartis Ag Triazolopirimidin-vegyületek és alkalmazásaik
CN107667092B (zh) 2015-03-25 2021-05-28 诺华股份有限公司 作为fgfr4抑制剂的甲酰化n-杂环衍生物
EP3310813A1 (fr) 2015-06-17 2018-04-25 Novartis AG Conjugués anticorps-médicament
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3472168B1 (fr) 2016-06-20 2024-01-10 Novartis AG Formes cristallines d'un composé de triazolopyrimidine
WO2017221092A1 (fr) 2016-06-20 2017-12-28 Novartis Ag Composés de triazolopyridine et leurs utilisations
CN109790166A (zh) 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
US11179413B2 (en) 2017-03-06 2021-11-23 Novartis Ag Methods of treatment of cancer with reduced UBB expression
WO2018185618A1 (fr) 2017-04-03 2018-10-11 Novartis Ag Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US20200270334A1 (en) 2017-05-24 2020-08-27 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines à greffe de cytokine-anticorps anti-interleukine-7 et procédés d'utilisation dans le traitement du cancer
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021524484A (ja) 2018-07-10 2021-09-13 ノバルティス アーゲー ３−（５−ヒドロキシ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の処置におけるその使用
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
KR102643582B1 (ko) 2018-07-25 2024-03-05 어드밴스드 엑셀러레이터 어플리케이션즈 안정한 농축 방사성 핵종 복합체 용액
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
JP7328323B2 (ja) 2018-08-17 2023-08-16 ノバルティス アーゲー ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物
WO2020064693A1 (fr) 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Polythérapie
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
CA3127502A1 (fr) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
CN113329792A (zh) 2019-02-15 2021-08-31 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2020165833A1 (fr) 2019-02-15 2020-08-20 Novartis Ag Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
KR20210141621A (ko) 2019-03-22 2021-11-23 스미토모 다이니폰 파마 온콜로지, 인크. Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
EP4077389A1 (fr) 2019-12-20 2022-10-26 Novartis AG Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
EP4204020A1 (fr) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Méthode de traitement de cancers exprimant le psma
WO2022043556A1 (fr) 2020-08-31 2022-03-03 Novartis Ag Composition pharmaceutique stable
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
WO2022195551A1 (fr) 2021-03-18 2022-09-22 Novartis Ag Biomarqueurs pour le cancer et leurs méthodes d'utilisation
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20230170039A (ko) 2021-04-13 2023-12-18 뉴베일런트, 아이엔씨. Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023008978A1 (fr) * 2021-07-30 2023-02-02 아주대학교산학협력단 Composition ciblant le sncg pour le traitement ou le diagnostic d'une maladie dégénérative
WO2023214325A1 (fr) 2022-05-05 2023-11-09 Novartis Ag Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2
WO2023225320A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées
WO2023225336A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
WO2024023666A1 (fr) 2022-07-26 2024-02-01 Novartis Ag Formes cristallines d'un inhibiteur de kars dependant d'akr1c3

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000082A1 (fr) * 1994-06-24 1996-01-04 Cortecs Limited Utilisation medicale de la bromelaine
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
WO1998028292A1 (fr) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Nouveaux composes renfermant de la piperidine
WO1998037881A1 (fr) * 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
WO1999001449A1 (fr) * 1997-06-30 1999-01-14 Novartis Ag 4,5-diaryle imidazoles substituees en position 2
WO1999057101A1 (fr) * 1998-05-05 1999-11-11 F. Hoffmann-La Roche Ag Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase
WO1999061440A1 (fr) * 1998-05-26 1999-12-02 Smithkline Beecham Corporation Nouveaux composes d'imidazole substitue

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000082A1 (fr) * 1994-06-24 1996-01-04 Cortecs Limited Utilisation medicale de la bromelaine
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
WO1998028292A1 (fr) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Nouveaux composes renfermant de la piperidine
WO1998037881A1 (fr) * 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
WO1999001449A1 (fr) * 1997-06-30 1999-01-14 Novartis Ag 4,5-diaryle imidazoles substituees en position 2
WO1999057101A1 (fr) * 1998-05-05 1999-11-11 F. Hoffmann-La Roche Ag Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase
WO1999061440A1 (fr) * 1998-05-26 1999-12-02 Smithkline Beecham Corporation Nouveaux composes d'imidazole substitue

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. M. BADGER ET AL: "SB 203580 Inhibits p38 Mitogen-Activated Protein Kinase, Nitric Oxide Production, and iNducible Nitric Oxide Synthase in Bovine Cartillage-Derived Chondrocytes", THE JOURNAL OF IMMUNOLOGY, vol. 161, 1998, pages 467 - 473, XP002134932 *
HENRY J R ET AL: "Potent inhibitors of the map kinase p38", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 8, no. 23, 1 December 1998 (1998-12-01), pages 3335 - 3340, XP004143754, ISSN: 0960-894X *
J. R. JACKSON ET AL: "Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 284, no. 2, 1998, pages 687 - 692, XP002134931 *
K. MIYAZAWA ET AL: "Regulation of Interleukin-1-beta-induced Interleukin-6 Gene Expression in Human Fibroblast-like Synoviocytes by p38 Mitogen-activated Protein Kinase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 38, 18 September 1998 (1998-09-18), pages 24832 - 24838, XP002134930 *

Also Published As

Publication number Publication date
EP1143957A3 (fr) 2002-02-27
IL143236A0 (en) 2002-04-21
AU776788C (en) 2005-10-27
EP1143957A2 (fr) 2001-10-17
KR100609800B1 (ko) 2006-08-09
HUP0104693A2 (hu) 2002-03-28
JP2002532415A (ja) 2002-10-02
HUP0104693A3 (en) 2003-12-29
KR20010093840A (ko) 2001-10-29
AU776788B2 (en) 2004-09-23
AU2185800A (en) 2000-07-03
WO2000035436A2 (fr) 2000-06-22
CA2346448A1 (fr) 2000-06-22

Similar Documents

Publication Publication Date Title
WO2000035436A3 (fr) Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
WO2001005392A3 (fr) Traitement des douleurs chroniques par des inhibiteurs de mek
WO2000040235A3 (fr) Traitement de l'asthme a l'aide d'inhibiteurs de mek
WO2001005391A3 (fr) Methode de traitement de la douleur chronique utilisant des inhibiteurs mek
BR9916536A (pt) Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
IL147618A0 (en) Method for treating chronic pain using mek inhibitors
AU5610398A (en) Method of treating or preventing septic shock by administering a mek inhibitor
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
KR930703001A (ko) 전신 홍반성낭창의 치료방법
NO996578L (no) Urokinase-inhibitorer
HUP0104745A2 (hu) Csípőbél epesav transzport inhibitorok és epesav elvonószerek kombinációi szív-érrendszeri indikációkhoz
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
DE69528528T2 (de) Thrombin-inhibitoren
ATE214928T1 (de) Thrombininhibitoren
PL353785A1 (en) Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor
EA200100571A1 (ru) Комбинированный способ лечебного воздействия, включающий применение лучевой терапии и ингибитора циклооксигеназы-2(cox-2) для лечения неоплазии
WO2002030353A3 (fr) INHIBITEURS DU NF-λB
WO2004043456A8 (fr) Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
WO1998036730A3 (fr) Compositions de traitement de l'acne rosacee
BR9915031A (pt) Processos e composições para a inibição de polimerização de hidrocarbonetos etilenicamente insaturados
WO2004050837A3 (fr) Traitement de troubles associes a un dommage a l'adn
WO2002039994A3 (fr) Methodes de traitement et de prevention des calculs urinaires
AU1034901A (en) Method and installation for treating effluents, comprising an additional treatment of the sludge by ozonisation
AU9802798A (en) Gas treating solution corrosion inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2346448

Country of ref document: CA

Ref document number: 2346448

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 21858/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 511207

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001/03253

Country of ref document: ZA

Ref document number: 200103253

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 143236

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999966278

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09868120

Country of ref document: US

Ref document number: 2001/01707

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 587757

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017007502

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999966278

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1020017007502

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 21858/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020017007502

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999966278

Country of ref document: EP